Brandon Milliken

Title: Innovations in Obesity Treatment: The Work of Brandon Milliken

Introduction

Brandon Milliken is an innovative inventor based in Syracuse, NY. He has made significant contributions to the field of obesity treatment through his research and patent work. His focus on dual agonism of specific receptors has the potential to revolutionize how obesity and type 2 diabetes mellitus (T2DM) are treated.

Latest Patents

Milliken holds a patent for a groundbreaking invention titled "Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors." This patent describes a series of chimeric peptides designed to provide a mechanism for treating obesity in conjunction with T2DM. The peptides target the anorectic neuropeptide Y-receptor (Y2-R) and the glucoregulatory receptor GLP1-R. Preliminary results indicate that, depending on the selected peptide, once-daily administration can suppress food intake in male and female rats by 12-65% compared to baseline conditions. Additionally, glucose tolerance can be improved, and the peptides demonstrate Y1-receptor agonism, which protects beta-islet cells from inflammatory damage.

Career Highlights

Brandon Milliken is affiliated with Syracuse University, where he conducts his research. His work is characterized by a commitment to addressing critical health issues through innovative solutions. His research has garnered attention for its potential to provide safe and effective treatments for obesity and T2DM.

Collaborations

One of Milliken's notable collaborators is Robert P. Doyle. Their partnership has contributed to the advancement of research in the field of obesity treatment.

Conclusion

Brandon Milliken's innovative work in developing peptide multi-agonists represents a significant advancement in the treatment of obesity and T2DM. His research holds promise for improving health outcomes and offers a new approach to managing these prevalent conditions.